ProShare Advisors’s AC Immune ACIU Stock Holding History

ProShare Advisors’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-11,230	Closed	-$56K	–	2196
2021 Q4	$56K	Sell	11,230 -5,806	-34%	-$33.7K	﹤0.01%	2273
2021 Q3	$114K	Buy	17,036 +3,983	+31%	+$28.5K	﹤0.01%	1895
2021 Q2	$104K	Buy	+13,053	New	+$90.2K	﹤0.01%	2286
2021 Q1	–	Sell	-11,072	Closed	-$57K	–	2258
2020 Q4	$57K	Sell	11,072 -508	-4%	-$2.59K	﹤0.01%	2037
2020 Q3	$57K	Buy	11,580 +98	+0.9%	+$703	﹤0.01%	1583
2020 Q2	$77K	Buy	+11,482	New	+$83.4K	﹤0.01%	1599
2020 Q1	–	Sell	-14,611	Closed	-$124K	–	1163
2019 Q4	$124K	Sell	14,611 -3,679	-20%	-$24.5K	﹤0.01%	1668
2019 Q3	$91K	Sell	18,290 -1,428	-7%	-$7.65K	﹤0.01%	1561
2019 Q2	$109K	Sell	19,718 -3,197	-14%	-$16.3K	﹤0.01%	1522
2019 Q1	$116K	Buy	22,915 +3,473	+18%	+$22.1K	﹤0.01%	1556
2018 Q4	$184K	Buy	+19,442	New	+$184K	﹤0.01%	1390

Other funds holding ACIU

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

ProShare Advisors's ACIU Position: Q1 2022 in Review

ProShare Advisors sold out of AC Immune (ACIU) in Q1 2022, closing a stake of 11,230 shares — an estimated $56K sold.

ProShare Advisors first reported a position in ACIU in Q4 2018 and held it in 11 quarters. The position peaked at $184K in Q4 2018. 36 funds tracked by Wall St. Rank hold ACIU as of Q1 2022.

ProShare Advisors reported no remaining AC Immune position as of Q1 2022 after selling out during the quarter.
ProShare Advisors sold 11,230 AC Immune shares in Q1 2022, an estimated $56K.
ProShare Advisors first reported a position in AC Immune in Q4 2018 and held it in 11 quarters.
ProShare Advisors's AC Immune position peaked at $184K in Q4 2018.
36 funds tracked by Wall St. Rank held AC Immune as of Q1 2022.

Based on ProShare Advisors's 13F filing for Q1 2022, filed 10 May 2022.